Receipt date: 03/27/2019
`
`Substitute for form 1449/PTO
`
`Complete ifKnown
`
`E uivalent of Form PTO/SB/08b
`
`-09)
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`NON PATENT LITERATURE DOCUMENTS
`
`Examiner
`Initials"<
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when
`appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.),
`date, page(s), volume-issue number(s), publisher, city and/or country where published
`
`“Products,” Cepheid, Inc., Sunnyvale, California, United States,
`https://web.archive.org/web/20040407201033/http://cepheid.com:80/pages/products.htm
`l, archived April 7, 2004.
`
`“Cepheid — Products,” Cepheid, Inc., Surmyvale, California, United States,
`https://web.archive.org/web/2004/0614174818/https://www.cepheid.com:80/Sites/cephe
`id/content.cfm?id=158, archived June 14, 2004.
`
`Belgrader, P., et al., “A microfluidic cartridge to prepare spores for PCR analysis,”
`Biosensors & Bioelectronics, Vol. 14: 849-852 (2000).
`
`
`
`
`
`Ulrich, M. P., et al., “Evaluation of the Cepheid GeneXpert® system for detecting
`Bacillu antracis,” Journal of Applied Microbiology, Vol. 100: 1011-1016 (2006).
`
`McMillan, W. A., “Real-time point-of-care molecular detection of infectious disease
`agents,” American Clinical Laboratory, Vol. 21(1): 29-31 (2002).
`
`Meehan, P. J., et al., “Responding to Detection of Aerosolized Bacillus anthracis by
`Autonomous Detection Systems in the Workplace,” Morbidity and Mortality Weekly
`Report: Recommendations and Reports, Vol. 53 (7): 1-12 (2004).
`
`Petersen, K., et al., “IVD systems in bioterrorism response,” IVDT: Beyond Clinical
`Diagnostics, Vol. 8(4): 35-40 (2002).
`
`“Cepheid Granted US Patent Covering Key Internal Control Method for Ensuring
`Accurate DNA Test Results,” Cepheid Inc., Surmyvale, California, United States,
`November 27, 2001.
`
`Piccolo® Operator’s Manual, Abaxis, Inc., Union City, California, United States, March
`200 1 .
`
`von SCHENCK, H., et al., "Evaluation of "HemoCue," a New Device for Determining
`Hemoglobin," Clin. Chem, Vol. 32(3): 526-529 (1986)
`
`Examiner
`
`Signature
`
`Date
`
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
`and not considered. Include copy of this form with next communication to applicant.
`1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
`ALL REFERENCES CONS IDERED EXCEPT WHERE LINED THROUGH .
`/M . P u L/
`
`

`

`NON PATENT LITERATURE DOCUMENTS
`
`Examiner
`Initials"<
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when
`appropriate), title of the item (book, magazine, journal, serial, symposium, catalog,
`etc.), date, page(s), volume number, publisher, city and/or country where published
`
`Neufeld, L., et al., "Hemoglobin measured by Hemocue and a reference method in
`venous and capillary blood: A validation study," Salud Publica de Mexico, Vol. 44(3):
`219-227 (2002).
`
`HemoCue Hb 201+ Operating Manual, HomeCue AB, Angelholm Sweden,
`
`Receipt date: 03/27/2019
`
`Substitute for form 1449/PTO
`
`Complete ifKnown
`
`E uivalent of Form PTO/SB/08b
`
`-09)
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`www.hemocue.com
`
`1292586371
`
`Examiner
`.
`Slgnature
`
`.
`M h
`’/ la ae
`
`l p L P
`a “gt-3% ’1
`
`Date
`.
`Con51dered
`
`O 7 / 1 8 f 2 O 1 9
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
`and not considered. Include copy of this form with next communication to applicant.
`1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
`ALL REFERENCES CONS IDERED EXCEPT WHERE LINED THROUGH .
`/M . P u L/
`
`